CHEK2 and central nervous system cancer: For example, the Cre/Lox mouse model hGFAP-Cre+;p53lox/lox;Ptenlox/+ of glioma which results in 73% of mice developing grade III and grade IV gliomas at a median latency of seven months (68); the RCAS/Ntv-a mouse model Chk2+/− of glioma which presents an average survival of 55 days, and with 40% of mice developing grade IV gliomas (69).